Insider Selling: IDEXX Laboratories (NASDAQ:IDXX) EVP Sells 1,758 Shares of Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP Nimrata Hunt sold 1,758 shares of IDEXX Laboratories stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the transaction, the executive vice president directly owned 18,141 shares in the company, valued at $11,511,734.37. The trade was a 8.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Nimrata Hunt also recently made the following trade(s):

• On Thursday, February 26th, Nimrata Hunt sold 2,693 shares of IDEXX Laboratories stock. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock traded down $29.78 during midday trading on Thursday, hitting $618.92. 611,044 shares of the company’s stock were exchanged, compared to its average volume of 517,285. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The stock has a market cap of $49.28 billion, a price-to-earnings ratio of 47.35, a price-to-earnings-growth ratio of 3.86 and a beta of 1.66. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The firm’s 50 day simple moving average is $669.92 and its 200 day simple moving average is $668.75.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the company posted $2.53 EPS. IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IDXX. Blalock Williams LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $590,000. New York State Common Retirement Fund increased its stake in shares of IDEXX Laboratories by 6.8% in the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock worth $38,477,000 after buying an additional 3,820 shares during the last quarter. Mediolanum International Funds Ltd increased its stake in shares of IDEXX Laboratories by 14.5% in the third quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock worth $24,441,000 after buying an additional 4,909 shares during the last quarter. Arkadios Wealth Advisors bought a new stake in shares of IDEXX Laboratories in the second quarter worth $405,000. Finally, Principal Financial Group Inc. raised its holdings in IDEXX Laboratories by 16.7% in the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after acquiring an additional 187,967 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Piper Sandler cut their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. UBS Group cut their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research report on Tuesday, February 3rd. Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Barclays dropped their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.